RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
RT @OhioHealthMS: Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https:/…
Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https://t.co/0IodIEW3TW
#MS study on adherence to 9 disease-modifying therapies indicates comparable adherence between oral and injectables https://t.co/QaGLlRUmDi
Adherence to disease-modifying therapies & its impact on relapse, health resource utilization, & costs among pwMS https://t.co/PKDHh7YNzl
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among… https://t.co/InLz1vp7Hu